课题基金 / 基金详情

Unravelling a Novel Mode of Multiple Antibiotic Resistance: Mechanism and Inhibition of Radical-SAM RNA Methyltransferases

Unravelling a Novel Mode of Multiple Antibiotic Resistance: Mechanism and Inhibition of Radical-SAM RNA Methyltransferases
揭示多重抗生素耐药性的新模式:Radical-SAM RNA 甲基转移酶的机制和抑制
批准号:
BB/J017906/1
负责人:
James Spencer
金额:
$43.76万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --

项目摘要

项目成果

James Spencer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Many chemical reactions are difficult to accomplish in the laboratory. However, in many cases biological systems have evolved specialised mechanisms that enable them to carry out these intrinsically difficult processes. Consequently the range of chemical structures able to be produced in nature is considerably greater than can currently be produced in the laboratory. As many such structures have useful properties, such as pharmaceutical activity, understanding how these are made in nature will expand our ability to make new molecules with a wide range of potential applications.It is now clear that nature achieves many of these intrinsically unfavourable reactions through the action of specific biological catalysts- enzymes. In particular, a large group known as the radical SAM enzymes are responsible for catalysing a diverse range of these "difficult" chemistries. Here we propose to study one such enzyme, known as Cfr, that introduces a specific modification to the bacterial ribosome. The ribosome is the component of the bacterial cell that is responsible for synthesising proteins and as such is essential to the viability of the bacterium. Many antibiotics act by poisoning the bacterial ribosome, but the Cfr enzyme causes a specific modification to the ribosome that makes Cfr-containing bacteria resist their activity. In particular, Cfr makes bacteria resistant to linezolid, an antibiotic that is particularly important as it represents a last line of defence against many bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) that are no longer easily treatable with other types of drugs. Cfr is beginning to spread through the bacterial population, potentially threatening our ability to use linezolid to treat serious infections. However, many aspects of the way that Cfr modifies the ribosome remain to be investigated. Improving our understanding of how enzymes like Cfr function may both permit us to develop drugs that block their activity, and enable us to exploit their ability to perform "difficult" chemical reactions to synthesise new and potentially useful moleculesIn this proposal, we will develop tools to investigate the activity of Cfr. We will use these to obtain fundamental information about how Cfr recognises a specific portion of the ribosome and how this site is selectively modified. We will also use the methods that we develop to screen a limited selection of synthetic molecules with the intention of identifying some that are able to block Cfr activity. We will establish, at a near atomic level of detail, how the molecules we identify are bound by Cfr, and how Cfr recognises the ribosome. The information we obtain will identify strategies for countering the activity of Cfr, that may prolong the therapeutically useful lifetime of linezolid, The application will also strengthen the UK knowledge and skills base with respect to the radical SAM enzyme family. Radical SAM enzymes are attracting increasing attention, due to the extraordinary range of reactions that they can catalyse, but there remain relatively few UK research groups active in this area. Our proposal will build capacity in an area of growing clinical and biotechnological relevance.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41467-017-02714-7
发表时间: 2018-02-13
期刊: Nature communications
影响因子: 16.6
作者: [Ranasinghe RT, Challand MR, Ganzinger KA, Lewis BW, Softley C, Schmied WH, Horrocks MH, Shivji N, Chin JW, Spencer J, Klenerman D]
通讯作者: Klenerman D
DOI: 10.1371/journal.pone.0067979
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者: [Challand MR, Salvadori E, Driesener RC, Kay CW, Roach PL, Spencer J]
通讯作者: Spencer J
DOI: 10.1007/978-1-4939-9674-2_7
发表时间: 2019
期刊: Methods in molecular biology
影响因子: --
作者: [Kristina A. Ganzinger;M. R. Challand;J. Spencer;D. Klenerman;Rohan T. Ranasinghe]
通讯作者: Kristina A. Ganzinger;M. R. Challand;J. Spencer;D. Klenerman;Rohan T. Ranasinghe
Conference Abstract
会议摘要
DOI: --
发表时间: 2015
期刊:
影响因子: --
作者: [Challand MR]
通讯作者: Challand MR
LSAMP BD: LSU BD 9 2022 Cohort, LA-BRIDGE: Louisiana Broadening Resources for Increasing Diversity in Graduate Education
  • 批准号:
    2204741
  • 项目类别:
    Standard Grant
  • 资助金额:
    $107.5万
  • 财政年份:
    2022
  • 负责人:
    James Spencer
  • 依托单位:
Mechanistic diversity, post-translational carbamylation, and inhibitor susceptibility in the OXA beta-lactamase family
  • 批准号:
    BB/W001187/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $103.29万
  • 财政年份:
    2021
  • 负责人:
    James Spencer
  • 依托单位:
Graduate Research Fellowship Program (GRFP)
  • 批准号:
    2136519
  • 项目类别:
    Fellowship Award
  • 资助金额:
    $88.32万
  • 财政年份:
    2021
  • 负责人:
    James Spencer
  • 依托单位:
Carbapenem Antibiotic Resistance in Enterobacteriaceae: Understanding Interactions of KPC Carbapenemases with Substrates and Inhibitors
  • 批准号:
    MR/T016035/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $86.54万
  • 财政年份:
    2020
  • 负责人:
    James Spencer
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: